Immune cells that produce and release opioid peptides at inflammation sites can be pharmacologically targeted for localized pain control — peripheral opioid analgesia without central addiction, tolerance, or sedation.
Key findingPeripheral opioid analgesia from immune cell-derived peptides can be enhanced by: recruiting more opioid-producing leukocytes, increasing per-cell opi
What the researchers found
Peripheral opioid analgesia from immune cell-derived peptides can be enhanced by: recruiting more opioid-producing leukocytes, increasing per-cell opioid release, or applying peripherally-restricted opioid agonists — achieving pain control without CNS side effects.
Why it matters
Relevant for opioid-peptides, pain, immune-function.
How the study worked
review study on opioid-peptides, pain.
What this study cannot tell us
See abstract.
How to read the evidence
moderate evidence.
When this study was published
Published in 2007.
The bigger picture
Advances peptide research.
Questions still open
- Further research needed.
- Clinical translation to evaluate.
Common questions
What was studied?
What was found?
Read the original research
Targeting of opioid-producing leukocytes for pain control.
Neuropeptides, 41(6), 355-63
Citation
Machelska, Halina. (2007). Targeting of opioid-producing leukocytes for pain control.. Neuropeptides, 41(6), 355-63.